351P - Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated Glioblastoma

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Central Nervous System Malignancies
Presenter Leonardo Rojas
Citation Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366
Authors L. Rojas1, A. Ruiz-Patiño2, A.F. Cardona3, O. Arrieta4, Z. Zatarain-Barrón4
  • 1School Of Medicine, Pontificia Universidad Javeriana, 220246 - Bogotá/CO
  • 2School Of Medicine, Hospital Universitario San Ignacio-Pontificia Universidad Javeriana, 110231 - Bogotá/CO
  • 3Clinical Oncology, Foundation for Clinical and Applied Cancer Research FICMAC, Bogotá/CO
  • 4Thoracic Oncology Unit And Laboratory Of Personalized Medicine, Instituto Nacional de Cancerologia - Mexico, 14080 - Ciudad de México/MX



Epilepsy is a common symptom in patients with glioblastoma (Gb). Levetiracetam (LEV), an antiepileptic drug (AED), enhances MGMT inhibition and reduces chemotherapy mediated neuronal toxicity, offering a theoretical benefit over other AEDs.


213 Hispanic patients were included. All patients underwent surgery (if feasible) followed by chemoradiation based on temozolomide. Type of AED was selected under treating physician discretion. Recorded variables included demographics, AED, dosage, MGMT status, performance status (PS) and type of surgical intervention. The relationship between overall survival (OS), AED and MGMT methylation status was explored.


Mean age was 53-yo (SD+/-14.7), 56.8% were male, 73% presented with epilepsy after diagnosis and 50.7% harbored methylated MGMT (metMGMT). 41% were treated with LEV, 26% were given another AED and 33% did not require any AED. AED indication was not associated with age (p = 0.087), PS (p = 0.78) anatomic tumor site (p = 0.34) or MGMT status (p = 0.98). Median OS was 25.8 months (95%CI 21.6-31.5), 27.9 months (95%CI 23.8-33.7) for those with metMGMT, and 11.83 months (95%CI 7.73-16.67) for non-metMGMT (p 


Retrospective analysis of this cohort suggests that LEV modifies OS in non-metMGMT Gb patients making it comparable to those with metMGMT. Further validation of this data in clinical trials is warranted.

Clinical trial identification

Legal entity responsible for the study

Leonardo Rojas




All authors have declared no conflicts of interest.